Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
Open Access
Abstract
Objective To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn’s disease (CD) naïve to immunosuppressants and biologics using a UK public payer perspective. Design A regression model estimated weekly CD Activity Index (CDAI)-based transition matrices (remission: CDAI Results Over 48 weeks, TC was associated with a higher clinical remission (CDAI Conclusion A TC strategy as used in the CALM trial is cost-effective compared with CM. Incorporating costs related to work productivity increases the economic value of TC. Cross-national inferences from this analysis should be made with caution given differences in healthcare systems. Trial registration number NCT01235689; Results.Keywords
Funding Information
- AbbVie
This publication has 25 references indexed in Scilit:
- Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohnʼs diseaseEuropean Journal of Gastroenterology & Hepatology, 2009
- Cost‐effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient‐level cost dataAlimentary Pharmacology & Therapeutics, 2009
- Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and AdultsGastroenterology, 2008
- The Direct and Indirect Cost Burden of Crohn's Disease and Ulcerative ColitisJournal of Occupational and Environmental Medicine, 2008
- Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's diseaseClinical Therapeutics, 2008
- The NICE Cost-Effectiveness ThresholdPharmacoEconomics, 2008
- Mapping from Disease-Specific Measures to Utility: An Analysis of the Relationships between the Inflammatory Bowel Disease Questionnaire and Crohn's Disease Activity Index in Crohn's Disease and Measures of UtilityValue in Health, 2007
- Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT RegistryClinical Gastroenterology and Hepatology, 2006
- Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective studyGut, 2004
- A comparison of the EQ‐5D and SF‐6D across seven patient groupsHealth Economics, 2004